Journal Sciences News
Womens Studies International Forum
Available online 16 May 2018
Vasculature on the clock: Circadian rhythm and vascular dysfunction
Publication date: Available online 17 May 2018
Source:Vascular Pharmacology Author(s): Sandra Crnko, Martin Cour, Linda W. Van Laake, Sandrine Lecour The master mammalian circadian clock (i.e. central clock), located in the suprachiasmatic nucleus of the hypothalamus, orchestrates the synchronization of the daily behavioural and physiological rhythms to better adapt the organism to the external environment in an anticipatory manner. This central clock is entrained by a variety of signals, the best established being light and food. However, circadian cycles are not simply the consequences of these two cues but are generated by endogenous circadian clocks. Indeed, clock machinery is found in mainly all tissues and cell types, including cells of the vascular system such as endothelial cells, fibroblasts, smooth muscle cells and stem cells. This machinery physiologically contributes to modulate the daily vascular function, and its disturbance therefore plays a major role in the pathophysiology of vascular dysfunction. Therapies targeting the circadian rhythm may therefore be of benefit against vascular disease.

Graphical abstract

image
Available online 16 May 2018
Asymmetric dimethylarginine contributes to retinal neovascularization of diabetic retinopathy through EphrinB2 pathway
Publication date: Available online 16 May 2018
Source:Vascular Pharmacology Author(s): Mei-Rong Du, Li Yan, Nian-Sheng Li, Yu-Jie Wang, Ting Zhou, Jun-Lin Jiang Diabetic retinopathy (DR) is a leading cause of vision loss with retinal neovascularization. This study aims to investigate whether Asymmetric dimethylarginine (ADMA) impacts the pathogenesis of DR via focusing on promoting retinal neovascularization and its underlying molecular mechanisms. Diabetic rats were induced by a single intraperitoneal injection of streptozotocin (STZ) for 20
Available online 8 May 2018
Cinnamaldehyde protects VSMCs against ox-LDL-induced proliferation and migration through S arrest and inhibition of p38, JNK/MAPKs and NF-
Available online 27 April 2018
Thyroid hormones affect nitrergic innervation function in rat mesenteric artery: Role of the PI3K/AKT pathway
Publication date: Available online 8 May 2018
Source:Vascular Pharmacology Author(s): Pablo Ll
Available online 22 April 2018
Perivascular fibrosis and the microvasculature of the heart. Still hidden secrets of pathophysiology?
Publication date: Available online 27 April 2018
Source:Vascular Pharmacology Author(s): Kirsti Ytrehus, Jean-S
Available online 17 April 2018
Innate and adaptive immunity in atherosclerosis
Publication date: Available online 22 April 2018
Source:Vascular Pharmacology Author(s): Kapka Miteva, Rosalinda Madonna, Raffaele De Caterina, Sophie Van Linthout Atherosclerosis is a chronic inflammatory disorder of the large and medium-size arteries characterized by the subendothelial accumulation of cholesterol, immune cells, and extracellular matrix. At the early onset of atherogenesis, endothelial dysfunction takes place. Atherogenesis is further triggered by the accumulation of cholesterol-carrying low-density lipoproteins, which acquire properties of damage-associated molecular patterns and thereby trigger an inflammatory response. Following activation of the innate immune response, mainly governed by monocytes and macrophages, the adaptive immune response is started which further promotes atherosclerotic plaque formation. In this review, an overview is given describing the role of damage-associated molecular patterns, NLRP3 inflammasome activation, and innate and adaptive immune cells in the atherogenesis process.

Graphical abstract

image
Available online 12 April 2018
Chebulagic acid Chebulinic acid and Gallic acid, the active principles of Triphala, inhibit TNF
Available online 12 April 2018
State of play and future direction with NOACs: An expert consensus
Publication date: Available online 12 April 2018
Source:Vascular Pharmacology Author(s): A.T. Cohen, G.Y. Lip, R. De Caterina, H. Heidbuchel, J.L. Zamorano, G. Agnelli, F. Verheugt, A.J. Camm Atrial fibrillation (AF) and venous thromboembolism (VTE) are cardiovascular conditions significant in contemporary practice. In both, the use of anticoagulation with vitamin K antagonists (VKAs) has been traditionally used to prevent adverse events. However, VKA therapy is associated with challenges relating to dose maintenance, the need to monitor anticoagulation, and bleeding risks. The non-vitamin K oral anticoagulants (NOACs) are becoming accepted as a clear alternative to VKA therapy for both AF and VTE management. The aim of this paper was to review contemporary evidence on the safety of NOACs in both conditions. A comprehensive literature review was conducted to explore key safety issues and expert consensus was achieved from eight professionals specialised in AF and VTE care. Consensus-based statements were formulated where available evidence was weak or contradictory. The expert statements in this paper form a key overview of the safety of NOACs compared with VKA therapy, and the comparative safety of different NOACs. It is apparent that a detailed patient work-up is required in order to identify and manage individual risk factors for bleeding and thrombosis prior to NOAC therapy. Additional measures, such as dose reductions, may also be used to maintain the safety of NOACs in practice.
Available online 11 April 2018
Systemic inflammatory response syndromes in the era of interventional cardiology
Publication date: Available online 12 April 2018
Source:Vascular Pharmacology Author(s): Riccardo Gorla, Raimund Erbel, Kim A. Eagle, Eduardo Bossone Systemic inflammatory response syndrome (SIRS), initially reported after cardiovascular surgery, has been described after various interventional cardiology procedures, including endovascular/thoracic aortic repair (EVAR/TEVAR), implantation of heart rhythm devices, percutaneous coronary intervention (PCI), electrophysiology procedures (EP), and transcatheter aortic valve implantation (TAVI). In these settings, a comprehensive understanding of the triggers, pathogenesis as well as a common diagnostic/therapeutic algorithm is lacking and will be discussed in this review. SIRS occurs in about 40% and 50% of patients undergoing TEVAR/EVAR and TAVI respectively; it affects 0.1% of patients undergoing implantation of heart rhythm devices. Prevalence is unknown after PCI or EP. Clinical presentation includes fever, dyspnoea/tachypnoea, tachycardia, weakness, chest pain and pericardial/pleural effusion. Several triggers can be identified, related to implanted devices, biomaterial, and procedural aspects (prolonged hypotension, aneurysm thrombus manipulation, active fixation atrial leads, coronary microembolization, balloon dilatation/stent implantantation, contrast medium, coronary/myocardial microperforation). Nonetheless, these triggers share three main pathogenic pathways leading to SIRS clinical manifestations: leucocytes activation, endothelial injury/activation, and myocardial/pericardial injury. Therapy consists of non-steroidal agents, with corticosteroids as second-line treatment in non-responders. Although a benign evolution is reported after implantation of heart rhythm devices, PCI and EP, major adverse events may occur after EVAR/TEVAR and TAVI at short- and mid-term follow up.
Available online 11 April 2018
Vascular wall regulator of G-protein signalling-1 (RGS-1) is required for angiotensin IImediated blood pressure control
Publication date: Available online 11 April 2018
Source:Vascular Pharmacology Author(s): Jyoti Patel, Surawee Chuaiphichai, Gillian Douglas, Caroline M. Gorvin, Keith M. Channon G-Protein coupled receptors (GPCRs) activate intracellular signalling pathways by coupling to heterotrimeric G-proteins that control many physiological processes including blood pressure homeostasis. The Regulator of G-Protein Signalling-1 (RGS1) controls the magnitude and duration of downstream GPCR signalling by acting as a GTPase-activating protein for specific G
April 2018
Intrauterine and lactational exposure to fluoxetine enhances endothelial modulation of aortic contractile response in adult female rats
Publication date: Available online 11 April 2018
Source:Vascular Pharmacology Author(s): Carolina M. Higashi, Simone M. Sartoretto, Cinthya Echem, Bruno F.C. Lucchetti, Maria Helena C. de Carvalho, Gislaine G. Pelosi, Phileno Pinge-Filho, Daniela C.C. Gerardin, Estef
April 2018
Editorial Board
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105

April 2018
The mechanisms behind decreased internalization of angiotensin II type 1 receptor
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): Jingwei Bian, Suli Zhang, Ming Yi, Mingming Yue, Huirong Liu The internalization of angiotensin II type 1 receptor (AT1R) plays an important role in maintaining cardiovascular homeostasis. Decreased receptor internalization is closely related to cardiovascular diseases induced by the abnormal activation of AT1R, such as hypertension. However, the mechanism behind reduced AT1R internalization is not fully understood. This review focuses on four parts of the receptor internalization process (the combination of agonists and receptors, receptor phosphorylation, endocytosis, and recycling) and summarizes the possible mechanisms by which AT1R internalization is reduced based on these four parts of the process. (1) The agonist has a large molecular weight or a stronger ability to hydrolyze phosphatidylinositol 4,5-bisphosphate (PtdIns (4,5) P2), which can increase the consumption of PtdIns (4,5) P2. (2) AT1R phosphorylation is weakened because of an abnormal function of phosphorylated kinase or changes in phospho-barcoding and GPCR
April 2018
Acarbose inhibits the proliferation and migration of vascular smooth muscle cells via targeting Ras signaling
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): Meng-Hsun Yu, Ming-Cheng Lin, Chien-Ning Huang, Kuei-Chuan Chan, Chau-Jong Wang Atherosclerosis involves the proliferation and migration of vascular smooth muscle cells (VSMCs). The migration of VSMCs from the media into the intima and their subsequent proliferation are important processes in neointima formation in atherosclerosis and restenosis after percutaneous coronary interventions. Acarbose, an alpha-glucosidase inhibitor, has been demonstrated to not affect serum levels of glucose and decrease the progression of intima-media thickening in rabbits fed with a high cholesterol diet (HCD). We previously showed that increased Ras protein levels enhanced the migration of TNF-
April 2018
A positive feedback loop between IL-1
April 2018
Hyperglycaemia disrupts conducted vasodilation in the resistance vasculature of db/db mice
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): Hamish A.L. Lemmey, Xi Ye, Hong C. Ding, Christopher R. Triggle, Christopher J. Garland, Kim A. Dora Vascular dysfunction in small resistance arteries is observed during chronic elevations in blood glucose. Hyperglycaemia-associated effects on endothelium-dependent vasodilation have been well characterized, but effects on conducted vasodilation in the resistance vasculature are not known. Small mesenteric arteries were isolated from healthy and diabetic db/db mice, which were used as a model of chronic hyperglycaemia. Endothelium-dependent vasodilation via the Gq/11-coupled proteinase activated receptor 2 (PAR2) was stimulated with the selective agonist SLIGRL. The Ca2+-sensitive fluorescent indicator fluo-8 reported changes in endothelial cell (EC) [Ca2+]i, and triple cannulated bifurcating mesenteric arteries were used to study conducted vasodilation. Chronic hyperglycaemia did not affect either EC Ca2+ or local vasodilation to SLIGRL. However, both acute and chronic exposure to high glucose or the mannitol osmotic control attenuated conducted vasodilation to 10
April 2018
UDP-sugars activate P2Y14 receptors to mediate vasoconstriction of the porcine coronary artery
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): Zainab S.B. Abbas, M. Liaque Latif, Natalia Dovlatova, Sue C. Fox, Stan Heptinstall, William R. Dunn, Vera Ralevic Aims UDP-sugars can act as extracellular signalling molecules, but relatively little is known about their cardiovascular actions. The P2Y14 receptor is a Gi/o-coupled receptor which is activated by UDP-glucose and related sugar nucleotides. In this study we sought to investigate whether P2Y14 receptors are functionally expressed in the porcine coronary artery using a selective P2Y14 receptor agonist, MRS2690, and a novel selective P2Y14 receptor antagonist, PPTN (4,7-disubstituted naphthoic acid derivative). Methods and results Isometric tension recordings were used to evaluate the effects of UDP-sugars in porcine isolated coronary artery segments. The effects of the P2 receptor antagonists suramin and PPADS, the P2Y14 receptor antagonist PPTN, and the P2Y6 receptor antagonist MRS2578, were investigated. Measurement of vasodilator-stimulated phosphoprotein (VASP) phosphorylation using flow cytometry was used to assess changes in cAMP levels. UDP-glucose, UDP-glucuronic acid UDP-N-acetylglucosamine (P2Y14 receptor agonists), elicited concentration-dependent contractions of the porcine coronary artery. MRS2690 was a more potent vasoconstrictor than the UDP-sugars. Concentration dependent contractile responses to MRS2690 and UDP-sugars were enhanced in the presence of forskolin (activator of cAMP), where the level of basal tone was maintained by addition of U46619, a thromboxane A2 mimetic. Contractile responses to MRS2690 were blocked by PPTN, but not by MRS2578. Contractile responses to UDP-glucose were also attenuated by PPTN and suramin, but not by MRS2578. Forskolin-induced VASP-phosphorylation was reduced in porcine coronary arteries exposed to UDP-glucose and MRS2690, consistent with P2Y14 receptor coupling to Gi/o proteins and inhibition of adenylyl cyclase activity. Conclusions Our data support a role of UDP-sugars as extracellular signalling molecules and show for the first time that they mediate contraction of porcine coronary arteries via P2Y14 receptors.
April 2018
Anakinra improves exercise peak aerobic capacity in patients with recently decompensated systolic heart failure
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): B.W. Van Tassell, M.M. Viscusi, M.G. Del Buono, J. Canada, S. Carbone, C. Trankle, L. Buckley, E. Lesnefsky, R. Arena, A. Abbate
April 2018
C subunit of F1/FO-ATP synthase as target for preventing the detrimental effect of myocardial ischemia/reperfusion injury
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): G. Aquila, G. Morciano, D. De Marco, D. Preti, G. Pedriali, C. Trapella, G. Campo, P. Rizzo, P. Pinton
April 2018
The human amniotic fluid stem cell secretome as new paracrine source to unlock endogenous cardiac regeneration
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): C. Balbi, L. Barile, S. Moimas, F. Moccia, A. Smits, F. Santini, D. Coviello, M.J. Goumans, M. Giacca, S. Bollini
April 2018
Indoxyl sulphate activates cardiac fibroblasts with enhanced collagen synthesis, upregulated angiotensin-neprilysin system, and paracrine induction of cardiomyocyte hypertrophy
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): C. Barisone, E. Lazzarini, C. Ruggeri, S. Garibaldi, P. Fabbi, D. Verzola, S. Ravera, C. Brunelli, G. Ghigliotti, P. Ameri
April 2018
Endothelial dysfunction and nutraceutical approaches: In vitro system to study the modulation of metabolic markers on human aortic endothelial cells
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): E. Bassino, I. Rinaldi, F. Gasparri, L. Munaron
April 2018
Generation of desmoplakin zebrafish models for arrhythmogenic cardiomyopathy as suitable systems for the identification of early pathogenic events and new therapeutic targets
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): G. Beffagna, A. Giuliodori, N. Facchinello, A. Vettori, K. Pilichou, S. Rizzo, F. Vanzi, M. Della Barbera, M. Cason, F. Argenton, N. Tiso, C. Basso, G. Thiene
April 2018
TRP expression signature in tumor-derived endothelial cells: Functional roles in prostate cancer angiogenesis
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): M. Bernardini, G. Grolez, A. Brossa, G. Trimaglio, A. Joshi, S. Castiglione, A. De Rosa, V. Mattot, G. Fromont-Hankard, F. Soncin, B. Bussolati, N. Prevarskaya, D. Gkika, A. Fiorio Pla
April 2018
Cardiac dysfunction after myocardial infarction: Role of pro-inflammatory extracellular vesicles
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): V. Biemmi, S. Panella, G. Milano, A. Ciullo, F. Muoio, E. Cervio, N. Pernigoni, T. Moccetti, T. Tallone, G. Vassalli, L. Barile
April 2018
Cardio-renal positive effects of dipeptidyl peptidase 4 inhibitor sitagliptin preserve diastolic function in a model of heart failure with preserved ejection fraction
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): D. Cappetta, A. De Angelis, L.P. Ciuffreda, G. Esposito, D. DAmario, A. Siracusano, L. Berrino, F. Rossi, K. Urbanek
April 2018
Sevoflurane preconditioning increases the release of cardioprotective exosomes from coronary endothelial cells
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): N. Terrasini, V. Casieri, A. Bini, M. Matteucci, V. Lionetti
April 2018
Therapeutic benefits of Phosphodiesterase-5 inhibition in chronic heart failure: A meta-analysis
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): R. De Vecchis, A. Cesaro
April 2018
Reciprocal regulation of GRK2 and bradykinin receptor stimulation modulate CA2+ intracellular level and permeability in endothelial cells
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): J. Gambardella, M. Bova, A. Petraroli, S. Loffredo, G. Iaccarino, B. Trimarco, D. Sorriento, M. Ciccarelli
April 2018
Role of SDF-1
April 2018
Signal transduction mechanisms of the calcium sensing receptor in neonatal rat cardiac fibroblasts and myocytes: A re-evaluation with real-time imaging and electrophysiological approaches
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): M. Ranieri, A. Gerbino, C. Carmone, I. Maiellaro, A.M. Hofer, L. Debellis, R. Caroppo, L. Guerra, S. Cotecchia, M. Colellla
April 2018
Effects of simulated hyperglycemia in vitro on insulin signaling in endothelial cells
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): P. Confalone, V. Doria, I. Minnucci, R. Madonna, R. De Caterina
April 2018
Chronic antihypertensive therapy with thiazide diuretics in older women and risk of osteoporosis: A recently much- debated association
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): R. De Vecchis, C. Ariano
April 2018
Impact of different modalities of clopidogrel administration on systemic oxidative stress in patients undergoing elective percutaneous coronary intervention
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): M.G. Del Buono, E.L. Iorio, L. Buckley, F. Mangiacapra, G. Di Sciascio
April 2018
Characterization of aspirated thrombi in patients with ST-elevation myocardial infarction
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): S. Del Turco, S. Sbrana, A. Pucci, G. Basta, G. Trianni, A.R. De Caterina, A. Rizza, M. Ravani, C. Palmieri, S. Berti, A. Mazzone
April 2018
Remodeling of atrial repolarization and atrial chamber deformation: A potential link in the development of atrial fibrillation?
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): L. Dini, L. Sartiani, L. Diolaiuti, M. Cameli, S. Mondillo, M. Maccherini, B. Le Grand, A. Mugelli, E. Cerbai
April 2018
Nanosponge-cyclodextrins functionalized with oxygen protects H9C2 cells from hypoxia/reoxygenation injury: Implications from an in vitro model
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): S. Femmin
April 2018
Apelin-induced cardioprotection involves PTEN inhibition by Src kinase
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): A. Folino, L. Accomasso, C. Giachino, G. Losano, P. Pagliaro, R. Rastaldo
April 2018
Nanoparticles at the neurovascular unit: In vitro and in vivo studies to assess the blood-brain barrier permeability and function
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): G. Forcaia, R. Dal Magro, B. Albertini, P. Blasi, F. Re, G. Sancini
April 2018
Catestatin induces glucose uptake and Glut4 trafficking in adult rat cardiomyocytes
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): S. Femmin
April 2018
Chamazulene prevents ROS production in human dermal fibroblast and bovine aortic endothelial cells exposed to oxidative stress
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): G. Querio, S. Antoniotti, F. Foglietta, R. Levi, C.M. Bertea, R. Canaparo, M.P. Gallo
April 2018
HGF-mimic antibody administration to counteract doxorubicin cardiotoxicity
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): S. Gallo, M. Spilinga, G. Ferrauto, E. Di Gregorio, A. Bonzano, P.M. Comoglio, T. Crepaldi
April 2018
Cross-talk between osteoblastic differentiated mesenchymal stem cells and endothelial cells in co-culture
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): T. Genova, E. Zicola, S. Petrillo, D. Chiabrando, E. Tolosano, F. Altruda, S. Carossa, F. Mussano, L. Munaron
April 2018
Functional characterization of a novel truncating mutation in Lamin A/C gene in a family with a severe cardiomyopathy with conduction defects
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): A. Gerbino, I. Bottillo, S. Milano, R. De Zio, G. Procino, P. Grammatico, M. Svelto, M. Carmosino
April 2018
Diabetes induces systemic microvascular remodelling
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): G. Graiani, A. Zecca, C.A.M. Lagrasta, A. Falco, C. Mangiaracina, B. Lorusso, C. Frati, D. Madeddu, R. Fioretzaky, F. Quaini
April 2018
Novel anti-obesity quercetin-derived Q2 prevents metabolic disorders in rats fed with high-fat diet
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): C. Rocca, L. Albano, M.C. Granieri, D. Amelio, I.C. Nettore, P.E. Macchia, S. Sinicropi, P. Ungaro, T. Angelone
April 2018
MIR-182 is a Tbx5 effector during heart development in zebrafish
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): E. Guzzolino, R. D'aurizio, M. Pellegrino, D. Garrity, N. Ahujah, M. Groth, M. Baugmart, C. Hatcher, A. Mercatanti, L. Mariani, Monica Evangelista, F. Russo, R. Fukuda, D. Stainier, L. Pitto
April 2018
Understanding the poor angiogenic capacity of the mammalian heart
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): T. Kocijan, A. Cappelletto, M. Rehman, Y.Q. Tang, S. Vodret, L. Zentilin, M. Giacca, S. Zacchigna
April 2018
Activated fibroblasts shape cardiomyocyte metabolism towards depressed mitochondrial oxidation and ATP depletion
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): E. Lazzarini, C. Ruggeri, S. Garibaldi, C. Brunelli, S. Ravera, P. Ameri

Complexities and challenges of genome diagnostics in inherited arrhythmic cardiomyopathies in the Padua experience
Publication date: April 2018
Source:Vascular Pharmacology, Volumes 103105 Author(s): E. Lazzarini, M. Cason, R. Celeghin, K. Ludwig, B. Bauce, I. Rigato, C. Calore, D. Corrado, G. Thiene, C. Basso, K. Pilichou
view: 150

Free Shipping on Orders $500 or More at DroneNerds.com!

Start: 03 Oct 2017 | End: 30 Apr 2018

Over 500 styles with butterfly element, save more with coupon RGbutterfly. Over $30, save $4. Over $40, save $6. Over $60, save $9. Over $80, save $12.

Start: 18 Apr 2017 | End: 12 Apr 2018

$9 OFF $88, $12 OFF $99, $15 OFF $129, offer valid until 04/30/2018.

Code: SHOPTD4

Start: 29 Oct 2017 | End: 30 Apr 2018

Search All Amazon* UK* DE* FR* JP* CA* CN* IT* ES* IN* BR* MX
Booking.com B.V. is based in Amsterdam in the Netherlands. Ready for some statistics? Our 1,534,024 properties, including 860,482 holiday rentals, are located in 123,105 destinations in 229 countries and territories, and are supported internationally by 198 offices in 70 countries.
2013 Copyright Techhap.com Mobile version 2015 | PeterLife & company
Skimlinks helps publishers monetize editorial content through automated affiliate links for products.
Terms of use Link at is mandatory if site materials are using fully or particulary.
Were treated to the site administrator, a cup of coffee *https://paypal.me/peterlife
Yandex.ru